Beactica AB, a fragment-based drug discovery company spun out of Uppsala University, today announced a new investment and the addition of Uppsala University Holding Company to its shareholders. The funding will support Beactica’s growing internal drug discovery pipeline.

Two leading companies in the area of fragment-based drug discovery (FBDD) today announced a new commercial alliance. IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Beactica AB, based in Uppsala, Sweden, will join forces to deploy a proprietary FBDD-based lead discovery and optimization platform.